Occupier

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

You can also keep up to date by following us on Twitter or LinkedIn

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

27 Jun 2019

27th June 2019 ‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team ‒ ‒ Acquisition driven by lead product Axumin® (fluciclovine F 18), a novel molecular imaging agent for use with PET imaging to detect recurrent prostate cancer, and a robust pipeline ‒ ‒ Combined business will leverage Bracco’s diagnostic modalities, global competencies, portfolio and financial resources ‒ BURLINGTON, Mass. and... Read more

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

16 Apr 2019

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual... Read more

Blue Earth Diagnostics celebrates five year anniversary

06 Mar 2019

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs... Read more

Vaccitech Awarded BARDA contract valued at $8.5M to conduct Phase II trial for Influenza Vaccine

04 Mar 2019

Oxford, UK – 4 March 2019 Vaccitech announced today that it has been awarded a contract valued at $8.5 million from the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, for the advanced clinical development of its recombinant Modified Vaccinia Ankara (MVA) vaccine candidate for prevention of seasonal... Read more

First production and administration of Axumin (fluciclovine (18F)) in Italy

14 Feb 2019

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed. Axumin is a novel molecular imaging agent approved in the European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected... Read more

News